CHMP gives positive opinion on Genmab partner's lung cancer drug

Janssen has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), including a recommendation that its candidate, amivantamab, is conditionally approved in Europe.

Photo: Tuala Hjarnø / Genmab / PR

Genmab's US partner, Janssen, has received a positive opinion from the CHMP, a committee that is part of the European Medicines Agency, and a recommendation that its candidate receives conditional marketing authorization in Europe for the treatment of non-small cell lung cancer. The dug is called amivantamab, with the commercial name Rybrevant.

CEO of Genmab Jan van de Winkel is especially pleased with this development, as this is the first time the CHMP has given a positive opinion on a product developed using Genmab's Duobody technology.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs